News that matter for June 9th AHL: BIO, SIGM, ENZ, OXM, MFRM, LMNR, ONVO, LQDT, ENZ, KMG

BioRad Labs announces its VARIANT II TURBO HbA1c Kit - 2.0 has obtained clearance from the FDA for use as an aid in diagnosing diabetes $BIO

Enzo Biochem Q3 adj. EPS ($0.07) vs ($0.06) Capital IQ single est; revs flat at $24.0 mln vs $24.40 mln Capital IQ single est  (3.10 +0.14) $ENZ

KMG Chemicals reports Q3 adj EPS of $0.35 vs $0.12 single estimate; revs -12% YoY to $74 mln vs $77.1 mln single estimate; narrows FY15 rev guidance  (31.52 +0.20) $KMG

Liquidity Services announced it has been awarded a contract extension by the U.S. Defense Logistics Agency, for its scrap property sales contract   (9.53 -0.07) LQDT

Organovo reports 2015 results and total contract bookings for exVive3D  (5.09 +0.08) ONVO

Limoneira beats by $0.03, beats on revs; guides FY15 EPS below consensus  (22.29 +0.65) LMNR

Oxford Industries beats by $0.09, beats on revs; guides Q2 above consensus; raises FY16 guidance  (81.01 +1.46) OXM

Sigma Designs prelim $0.09 vs $0.01 Capital IQ Consensus Estimate; revs $55.1 mln vs $53.48 mln Capital IQ Consensus Estimate SIGM

Mattress Firm reaffirms FY16 $2.50-2.70 vs $2.62 Capital IQ Consensus Estimate; raises revs guidance to $2.485-2.535 bln vs $2.49 bln Capital IQ Consensus Estimate MFRM